Brentuximab vedotin: targeting CD30 as standard in CTCL
Oncotarget
.
2018 Feb 10;9(15):11887-11888.
doi: 10.18632/oncotarget.24472.
eCollection 2018 Feb 23.
Authors
H Miles Prince
1
,
Ashish Gautam
1
,
Youn H Kim
1
Affiliation
1
H. Miles Prince: Division of Cancer Medicine, Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology and Epworth Healthcare, The University of Melbourne, Victoria, Australia.
PMID:
29552279
PMCID:
PMC5844715
DOI:
10.18632/oncotarget.24472
No abstract available
Keywords:
ALCANZA; CD30; CTCL; brentuximab vedotin.
Publication types
Editorial